Involuntary Memories Investigation in Schizophrenia

NCT ID: NCT03209778

Last Updated: 2021-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-29

Study Completion Date

2019-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with schizophrenia suffer from autobiographical memory disorders. Patients have difficulty to remember vividly personal past events when they are specifically asked for. Indeed, this task requires a good executive functioning to retrieve precise information stored in long term memory. Interestingly, executive functioning has been showed impaired in schizophrenia and studies showed that their autobiographical memory impairments were directed related to their executive dysfunction.

Yet, in daily life people remember more often autobiographical memories spontaneously, without trying voluntarily to recall them.

In that case, the involuntary recall of personal past events is much less sustained by executive functioning.

In this protocol the investigators would like to investigate and compare subjective characteristics of involuntary and voluntary autobiographical memories in order to highlight the role of executive dysfunction in patients' autobiographical memory impairments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Control participants without psychiatric nor neurological history

Group Type ACTIVE_COMPARATOR

Patients with Schizophrenia

Intervention Type OTHER

Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria

Patients with Schizophrenia

Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria

Group Type EXPERIMENTAL

Patients with Schizophrenia

Intervention Type OTHER

Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients with Schizophrenia

Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- for patients only
* male or female
* age limits : 18-55 years old
* under the protection of health insurance
* who have signed up the consent form
* schizophrenia or schizo-affective disorder according to the DSM-5 criteria (APA, 2013).
* clinically stable for at least 2 months
* patients under guardianship or curatorship need agreement of their legal representative
* informed of the results of prior medical examination for controls only
* male or female
* age limits : 18-55 years old
* under the protection of health insurance
* who have sign up the consent form
* recruited from the general population and matched on gender, age years of schooling
* no psychiatric history (DSM-5)

Exclusion Criteria

* for both patients and controls
* current severe or unstable somatic illness
* neurological history (brain injury \> 15 minutes loss of consciousness , epilepsia, brain surgery…)
* current substance use disorder (DSM-5)
* current major depressive disorder (CDSS,BDI, HDRS)
* mental retardation (IQ \< 70, WAIS-4, f-NART)
* history of general anesthesia 3 months prior to the experiment
* pregnancy declared by the subject
* breast feeding
* current legal control
* in emergency situation
* included during exclusion period in another experiment
* for controls only
* taking of antipsychotic drugs for the 3 weeks prior to inclusion
* under guardianship or curatorship
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Les Hôpitaux Universitaires

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6620

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.